Large Volume Injection Devices for Self-Administration
|出版商||Greystone Research Associates||商品編碼||297898|
|自我施打用大量輸液設備 Large Volume Injection Devices for Self-Administration|
|出版日期: 2014年03月20日||內容資訊: 英文||
Greystone Research Associates is pleased to announce the publication of a new market study. Large Volume Injection Devices for Self-Administration: Products, Therapeutics, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for wearable devices capable of injecting or infusing therapeutic drugs in large volumes. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Biological drugs continue to increase in terms of the absolute number of new approved drugs and as a percent of all approved drugs. In two of the largest (in terms of revenue) and fastest growing therapeutic segments - autoimmune diseases and oncology - the majority of drugs consist of monoclonal antibodies (mAbs). Therapeutic drugs consisting of proteins and peptides present unique drug packaging and delivery challenges. Often the dosing volume required to achieve a therapeutic effect requires the drug to be delivered via infusion, resulting in logistical, cost and safety issues. Drug developers and their delivery technology partners are attempting to address this limitation. The development of injectors capable of delivering drug volumes of 2 mL or higher subcutaneously is one promising method. This report examines this new class of devices and analyzes their potential impact on biological drug delivery.